Prognostic significance of pretreatment F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using 131I-Rituximab

Acta Haematologica

Volumn 130, Issue 2, 2013, Pages 74-82

  Lim, Ilhan ^a,b   Park, Joon Yeun ^a   Kang, Hye Jin ^a   Hwang, Jae Pil ^a   Lee, Seung Sook ^a   Kim, Kyeong Min ^b   Choi, Tae Hyun ^b   Yang, Sung Hyun ^a   Kim, Byung Il ^a,b   Choi, Chang Woon ^a,b   Lim, Sang Moo ^a,b  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

18F FDG PET CT; Lymphoma; Prognosis; Radioimmunotherapy; Survival

Indexed keywords

CD20 ANTIBODY; FLUORODEOXYGLUCOSE F 18; RITUXIMAB; RITUXIMAB IODINE 131; UNCLASSIFIED DRUG; RADIOISOTOPE; RITUXIMAB I 131;

ADULT; AGED; ARTICLE; B CELL NON HODGKIN LYMPHOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TREATMENT RESPONSE; TUMOR VOLUME; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; HISTOLOGY; KAPLAN MEIER METHOD; PET-CT SCANNER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 84875681770     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000346436     Document Type: Article

References (24)

1. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL: 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449
2. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximabVrefractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269
3. Leahy MF, Seymour JF, Hicks RJ, Turner JH: Multicenter phase II clinical study of iodine-131Vrituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 4418-4425
4. Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF: A prospecti-e study of the separate predicti-e capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131Vrituximab radio-immunotherapy. Haematologica 2008; 93: 789-790
5. Bodet-Milin C, Kraeber-Bodere F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D: E-aluation of response to fractionated radioimmunotherapy with 90 Y-epratuzumab in non-Hodgkin's lymphoma by 18 F-fluorodeoxyglucose positron emission tomography. Haematologica 2008; 93: 390-397
6. Jacene HA, Filice R, Kasecamp W, Wahl RL: 18 F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009; 50: 8-17
7. Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S: FDG PET and 90 Y ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 2010; 54: 436-441
8. Torizuka T, Zasadny KR, Kison P-, Rommelfanger SG, Kaminski MS, Wahl RL: Metabolic response of non-Hodgkin's lymphoma to 131 I-anti-B1 radioimmunotherapy: E-aluation with FDG PET. J Nucl Med 2000; 41: 999-1005
9. Lopci E, Santi I, Derenzini E, Fonti C, Sa-elli G, Bertagna F, Bello M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S: FDGPET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study. Ann Oncol 2010; 21: 1877-1883
10. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Re-ised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586
11. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M, Huglo D: Pre-therapy 18 F-FDG PET quantitati-e parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 494-504
12. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, VVo K, Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804-1810
13. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Sil-erman DH, Parker E, Grillo-Lopez AJ: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803
14. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429-4431
15. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M: [ 18 F]fluoro-2-deoxy-D Vglucose positron emission tomography (FDG-PET) in aggressi-e lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381
16. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ: PET predicts prognosis after 1 cycle of chemotherapy in aggressi-e lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027
17. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR: FDG-PET after two to three cycles of chemotherapy predicts progression-free and o-erall sur-i-al in highgrade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523
18. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G: Prognostic Value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([ 18 F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [ 18 F] FDG-PET a Valid alternati-e to con-entional diagnostic methods? J Clin Oncol 2001; 19: 414-419
19. Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY: Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with RCHOP therapy. Ann Hematol 2010; 89: 985-991
20. Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, Napoli A, de Risi C, Spina A, Ricco R, Liso V, Specchia G: High Ki67 index and bulky disease remain significant ad-erse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol 2011; 126: 44-51
21. Nourigat C, Badger CC, Bernstein ID: Treatment of lymphoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen. J Natl Cancer Inst 1990; 82: 47-50
22. Knox SJ, Goris ML, Trisler K, Negrin R, Da-is T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Le-y R: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457-470
23. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991; 9: 918-928
24. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of hea-ily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573